BioPorto (OTC:THOXF, NASDAQ COPENHAG:BIOPO) A/S (OTCMKTA:THOXF) (CPH:BIOPO) CEO Peter Eriksen tells Proactive the Danish group has posted interim second-quarter results that saw strong sales of antibodies and research use only sales of its flagship NGAL Test, which provides an early risk assessment of acute kidney injury.
Eriksen says the in vitro diagnostics company's revenue from antibodies was up 118% and research use only sales of its proprietary NGAL Test in the US increased 84% in US dollars and 68% in Danish krone.